LAVA – Talk Bio

Actionable Insights Powered by AI

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

1 month ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

Lava cuts jobs by 30% after key drug discontinued

7 months ago talkbio0Tagged cash runway, Discontinuation (procedure), LAVA, LAVA-1266, mCRPC, restructuring, strategic alternatives

LAVA Therapeutics, restructuring, workforce reduction, LAVA-1207, discontinuation, mCRPC, LAVA-1266, strategic alternatives, cash runway